Glucocorticoid-induced osteoporosis: head-to-head drug study results

Denosumab is superior to risedronate in increasing bone-mineral density (BMD) at the lumbar spine in patients just starting or continuing steroid therapy, according to 12-month results of a 24-month randomised controlled study.